from the world's big
The DEA is finally changing how it regulates marijuana products
With the approval of a childhood epilepsy medication the federal government can no longer claim marijuana has no medical benefit.
- For the first time in nearly a half-century, the federal government has approved a medication with a cannabis compound.
- CBD is all the rage in health food stores, but credible research is needed to know what therapeutic applications hold up.
- DEA officer says this could signal a "sea change" in the legalization of cannabis-related products.
If you're confused about the legality of marijuana, you're not alone. While states have been in perpetual battle with the federal government since California legalized the medical usage of cannabis in 1996, things have been especially heated lately with more studies proving the clinical efficacy of the cannbidiols (CBD) contained in the marijuana plant.
It doesn't help that every coffee shop and health food store is taking advantage of this trend by selling eight-dollar bottles of cold brew coffee with CBD. Mass marketization was inevitable, certainly, but the pace with which CBD hit the shelves is astounding. The fact that it's being touted to cure every possible ailment imaginable does not help us figure out what CBS is actually useful for.
The cannabis plant has approximately 113 cannabinoids, of which CBD is one—it was first isolated in 1940. CBD interacts with our body's exogenous cannabinoid receptors and neurotransmitters. Since our body comes equipped with its own endocannabinoid system, responsible for pain, mood, memory, and, yes, appetite, we likely have a very long history with this plant. The munchies are real.
Among the many proposed therapeutic uses for CBD is treating two rare forms of childhood epilepsy. Clinical studies in this domain have been so successful that, for the first time ever, the DEA has stepped in to allow prescriptions of Epidiolex. CBD will not get you high—that's THC—but for the first time since marijuana was officially outlawed in 1970 the federal government is green lighting one its compounds.
Marijuana advocates have long known its classification as a Schedule 1 substance is more political than physiological. The DEA's drug scheduling chart includes five categories:
- Schedule 1: no accepted medical use; high potential for abuse. Drugs include marijuana, heroin, LSD, ecstasy, and peyote
- Schedule 2: high potential for abuse and dangerous. Drugs include Vicodin, OxyContin, fentanyl, Adderall, and Ritalin
- Schedule 3: moderate to low potential for abuse. Drugs include codeine, ketamine, anabolic steroids, and testosterone
- Schedule 4: low potential for abuse or dependence. Drugs include Xanax, Ativan, Valium, Tramadol, and Darvon
- Schedule 5: the lowest potential for abuse. Drugs include cough syrup, Lyrica, Parepectolin, and Lomotil
Since the Nixon era, cannabis consumers have had to rely on anecdotal evidence. (As a cancer survivor, I'll chime in that edibles were way more effective at quelling post-chemo stomach pains and returning my appetite, one of the many claimed applications.) Recent research shows a wide range of therapeutic applications, including helping opioid addicts manage pain, helping everyone deal with chronic pain, deal with stress (at low doses), ease pain associated with multiple sclerosis, and may even, somewhat counterintuitively, help combat the obesity epidemic.
As with all such studies, more research is needed. Advocates should welcome this. If it turns out that compounds in the cannabis plant do not really help opioid addicts manage pain, we shouldn't use it as a calling card for legalization (although this one is holding up). Now that at least one medication is FDA-approved, however, the DEA should immediately remove marijuana from its Schedule 1 listing. Those two facts cannot co-exist without obvious contradiction.
The mainstreaming of clinical research is also necessary to reduce cost. Right now, Epidiolex will run you $32,500 annually. Parents of children suffering from seizures don't deserve that kind of pain on top of what they already have to deal with, especially not in a medication with as common an ingredient as CBD.
And we might see that day soon. Barbara Carreno, the DEA's PR officer, recently said a "sea change" is possible within the entire CBD industry. As the cash rolls in, this is likely to be the case: CBD is expected to be worth $2 billion annually by 2022. It might not get you high, but most importantly, it will be available when you actually need it.
Join The Daily Show comedian Jordan Klepper and elite improviser Bob Kulhan live at 1 pm ET on Tuesday, July 14!
The team caught a glimpse of a process that takes 18,000,000,000,000,000,000,000 years.
- In Italy, a team of scientists is using a highly sophisticated detector to hunt for dark matter.
- The team observed an ultra-rare particle interaction that reveals the half-life of a xenon-124 atom to be 18 sextillion years.
- The half-life of a process is how long it takes for half of the radioactive nuclei present in a sample to decay.
Gender and sexual minority populations are experiencing rising anxiety and depression rates during the pandemic.
- Anxiety and depression rates are spiking in the LGBTQ+ community, and especially in individuals who hadn't struggled with those issues in the past.
- Overall, depression increased by an average PHQ-9 score of 1.21 and anxiety increased by an average GAD-7 score of 3.11.
- The researchers recommended that health care providers check in with LGBTQ+ patients about stress and screen for mood and anxiety disorders—even among those with no prior history of anxiety or depression.
Study findings<p>For the study, <a href="https://link.springer.com/article/10.1007/s11606-020-05970-4" target="_blank">published in the Journal of General Internal Medicine</a><em>, </em>Flentje and her team evaluated survey responses from nearly 2,300 individuals who identified as being in the lesbian, gay, bisexual, transgender, and queer (LGBTQ+) community. Most of the participants were white, while nearly 19 percent identified as a racial or ethnic minority. Multiple genders were represented with cisgender women (27.2 percent) and men (24.6 percent) making up a majority of the participants. Sixty-three percent had been assigned female at birth. For the most part, participants identified their sexual orientations as queer (40.3 percent), gay (36.5 percent), and bisexual (30.3 percent).</p><p>The JGIM study participants were recruited from the 18,000-participant <a href="https://pridestudy.org/" target="_blank">PRIDE Study</a> (Population Research in Identity and Disparities for Equality), which is the first large-scale, long-term national study focusing on American adults who identify as LGBTQ+. It conducts annual questionnaires to understand factors related to health and disease in this population. </p><p>Participants filled out an annual questionnaire (starting in June 2019) and a COVID-19 impact survey this past spring. Flentje noted that on an individual level, some people may not have experienced a big change in anxiety or depression levels, but for others there was. Overall, depression increased by a <a href="https://patient.info/doctor/patient-health-questionnaire-phq-9" target="_blank">PHQ-9 score</a> of 1.21, putting it at 8.31 on average. Anxiety went up by a <a href="https://www.mdcalc.com/gad-7-general-anxiety-disorder-7" target="_blank">GAD-7</a> score of 3.11 to an average of 8.89. Interestingly, the average PHQ-9 scores for those who screened positive for depression at the first 2019 survey decreased by 1.08. Those who screened negative for depression saw their PHQ-9 scores increase by 2.17 on average. As for anxiety, researchers detected no GAD-7 change among the study participants who screened positive for anxiety in the first survey, but did see an overall increase of 3.93 among those who had initially been evaluated as negative for the disorder. </p>
Risks among gender and sexual minorities<span style="display:block;position:relative;padding-top:56.25%;" class="rm-shortcode" data-rm-shortcode-id="fc3fd1ae68b77bbbf58a6995638d6d65"><iframe type="lazy-iframe" data-runner-src="https://www.youtube.com/embed/EnUqDjCqg0A?rel=0" width="100%" height="auto" frameborder="0" scrolling="no" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></span><p>The LGBTQ+ community is a vulnerable population to mental health concerns because of their fear of stigmatization and previous discriminatory experiences.</p> <p>Previous research by the Human Rights Campaign has found "that LGBTQ Americans are more likely than the <a href="https://medicalxpress.com/tags/general+population/" target="_blank">general population</a> to live in poverty and lack access to adequate medical care, paid <a href="https://medicalxpress.com/tags/medical+leave/" target="_blank">medical leave</a>, and basic necessities during the pandemic," said researcher Tari Hanneman, director of the health and aging program at the campaign.</p> <p>"Therefore, it is not surprising to see this increase in anxiety and depression among this population," Hanneman said in the release. "This study highlights the need for <a href="https://medicalxpress.com/tags/health+care+professionals/" target="_blank">health care professionals</a> to support, affirm and provide <a href="https://medicalxpress.com/tags/critical+care/" target="_blank">critical care</a> for the LGBTQ community to manage and maintain their mental health, as well as their physical health, during this pandemic."</p>
What should health care providers do?<p>The authors of the study recommend that health care providers check in with LGBTQ+ patients about stress and screen for mood and anxiety disorders in members of that community—even among those with no prior history of anxiety or depression.</p><p>As cases of COVID-19 continue to mount, the sustained social distancing, potential isolation, economic precariousness, and personal illness, grief, and loss are bound to have increased and varied impacts on mental health. Effective treatments may include individual therapy and medications as well as more large-scale coronavirus support programs like peer-led groups and mindfulness practices. </p><p>"It will be important to find out what happens over time and to identify who is most at risk, so we can be sure to roll out public health interventions to support the mental health of our communities in the best and most effective ways," said Flentje.</p>
What we know about black holes is both fascinating and scary.
- When it comes to black holes, science simultaneously knows so much and so little, which is why they are so fascinating. Focusing on what we do know, this group of astronomers, educators, and physicists share some of the most incredible facts about the powerful and mysterious objects.
- A black hole is so massive that light (and anything else it swallows) can't escape, says Bill Nye. You can't see a black hole, theoretical physicists Michio Kaku and Christophe Galfard explain, because it is too dark. What you can see, however, is the distortion of light around it caused by its extreme gravity.
- Explaining one unsettling concept from astrophysics called spaghettification, astronomer Michelle Thaller says that "If you got close to a black hole there would be tides over your body that small that would rip you apart into basically a strand of spaghetti that would fall down the black hole."